Discover the latest in health: evidence‑based wellness tips, medical breakthroughs, nutrition guidance, fitness insights, and expert advice for a healthier, happier life.
A new study demonstrates that artificial intelligence (AI) can significantly improve the accuracy of digital breast tomosynthesis (DBT), commonly known as 3D mammography, in detecting breast cancer without increasing the number of patients called back for additional imaging. This advancement offers a promising step forward in early cancer detection and could lead to more effective treatment outcomes. The findings come as Beth Israel Deaconess Medical Center (BIDMC) in Boston begins utilizing an AI-driven tool, Clairity Breast, to assess a woman’s risk of developing breast cancer within the next five years.
For decades, screening mammograms have primarily been used to identify existing breast cancer. Now, with the advent of AI technologies like Clairity Breast, these diagnostic tools are evolving into predictive ones. Authorized by the U.S. Food and Drug Administration (FDA) through the De Novo pathway, Clairity Breast represents a new class of medical technology, allowing healthcare providers to identify women at increased risk years before a traditional diagnosis might occur. This shift in approach could be particularly impactful, as the majority of women diagnosed with breast cancer have no known genetic mutation or family history of the disease.
The recent study, detailed in reports from Radiology Business and AuntMinnie, showed that AI assistance led to a statistically significant increase in cancer detection rates when radiologists reviewed DBT images. Importantly, the study too found that the use of AI did not lead to a higher recall rate – meaning fewer patients were unnecessarily called back for follow-up imaging due to false positives. What we have is a critical factor, as high recall rates can cause anxiety for patients and strain healthcare resources.
Clairity Breast, developed by Clairity Inc., derives its risk score directly and exclusively from a woman’s mammogram. The first clinical patient received a Clairity Breast cancer risk score on February 23, 2026, marking a historic milestone in women’s health. Massachusetts Governor Maura Healey applauded the innovation, stating, “Massachusetts has long been a leader in health care, tech and innovation, and we are committed to advancing solutions that improve people’s health and save lives. It’s great to see Clairity, a Boston-based company, using AI to facilitate more women understand their risk of breast cancer earlier.”
How Clairity Breast Works
The Clairity Breast platform analyzes mammogram images using sophisticated algorithms to identify subtle patterns and features that may indicate an increased risk of developing breast cancer. This analysis goes beyond what the human eye can typically detect, providing a more comprehensive assessment of risk. The FDA authorized the technology in 2025, recognizing its potential to improve breast cancer screening and early detection.
Beth Israel Deaconess Medical Center’s adoption of Clairity Breast builds on a growing trend of integrating AI into medical imaging. The hospital is part of Beth Israel Lahey Health, a healthcare system dedicated to expanding access to quality care and advancing medical science. The implementation of this technology is expected to enhance the capabilities of radiologists and improve patient outcomes.
Beyond Mammography: A New Era of Risk Assessment
Traditionally, breast cancer risk assessment has relied heavily on factors like family history and genetic testing. While these remain important considerations, they don’t capture the full picture. Clairity Breast offers a complementary approach, providing a personalized risk assessment based on an individual’s unique mammographic features. This is particularly valuable for women who may not have a strong family history or known genetic predisposition to the disease.
The development of Clairity Breast and its implementation at BIDMC represent a significant step toward more proactive and personalized breast cancer screening. As AI technology continues to evolve, it is likely to play an increasingly important role in early detection and prevention efforts. The ability to identify women at higher risk before cancer develops could lead to more targeted screening strategies and potentially reduce the burden of this disease.
Looking ahead, further research will be crucial to refine AI algorithms and validate their effectiveness across diverse populations. Continued collaboration between clinicians, researchers, and technology developers will be essential to unlock the full potential of AI in breast cancer care. The ongoing evaluation of Clairity Breast’s impact on patient outcomes will provide valuable insights into the future of breast cancer screening.
This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you discussed breast cancer screening options with your doctor? Share your thoughts in the comments below.